Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
KA - Kineta, Inc.
Market Cap 19.93M P/E - EPS this Y - Ern Qtrly Grth -
Income -20.88M Forward P/E -1.35 EPS next Y - 50D Avg Chg -20.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -66.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -86.00%
Recommedations 2.00 Quick Ratio 0.10 Shares Outstanding 12.26M 52W Low Chg 5.00%
Insider Own 34.89% ROA -114.08% Shares Float 7.98M Beta -
Inst Own 6.00% ROE - Shares Shorted/Prior 28.54K/90.71K Price 2.10
Gross Margin - Profit Margin - Avg. Volume 21,791 Target Price 13.50
Oper. Margin - Earnings Date Nov 1 Volume 13,493 Change -4.55%
Healthcare | Biotechnology | United States
About Kineta, Inc.

Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.

Kineta, Inc. News
10/04/24 Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
10/02/24 Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1
09/19/24 Kineta, Inc Transitioning from Nasdaq to OTC Markets
08/20/24 After 5 months of financial woes, Kineta restarts recruitment in Phase I/II trial
08/19/24 TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
08/19/24 Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
07/08/24 Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences
05/15/24 Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
04/08/24 Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
03:02 PM Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
03/12/24 KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported
02/29/24 Kineta Announces Restructuring and Exploration of Strategic Alternatives
02/22/24 Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium
02/14/24 Kineta to Present at Upcoming Investor Conferences
02/07/24 Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series
01/29/24 KA: Phase I/II Update
01/17/24 Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
01/04/24 Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event
12/15/23 Life Science Investor Forum: Presentations Now Available for Online Viewing
12/13/23 Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer
KA Chatroom

User Image Abo_Hamza Posted - 2 weeks ago

$KA so what does the report means ?

User Image Abo_Hamza Posted - 10/30/24

$KA may be 🤷‍♂️

User Image Abo_Hamza Posted - 10/30/24

$KA am i the only one who feels we should get some updates now either positive or negative !!!!!!!!!!!??

User Image Abo_Hamza Posted - 10/28/24

$KA we should get news any time🤷‍♂️🤷‍♂️

User Image Abo_Hamza Posted - 10/26/24

$KA should we expect new Pre-Market Monday i hope sooooo

User Image Abo_Hamza Posted - 10/23/24

$KA 20 days now sooooo!!!!

User Image Abo_Hamza Posted - 1 month ago

$KA

User Image Fredmark Posted - 1 month ago

@ElliottwaveForecast

User Image johncliff669 Posted - 1 month ago

KANT for some reason comes up on my Fidelity account I have 1 share of it to watch it closely but it comes up as $KA everywhere else.

User Image Line_Line Posted - 1 month ago

@johncliff669 $KA

User Image Line_Line Posted - 1 month ago

@ians don’t forget about $KA

User Image Abo_Hamza Posted - 1 month ago

$KA what is the news means

User Image Abo_Hamza Posted - 1 month ago

$KA Shoukd we recieve any news today PM

User Image Abo_Hamza Posted - 1 month ago

$KA frist ten days extension should be over ?? Any expectations here ?

User Image Abo_Hamza Posted - 1 month ago

$KA finally some good news

User Image themacromindset Posted - 1 month ago

$KA $KA Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1

User Image tradestockforfun Posted - 09/26/24

$KA Is anyone still around from PTI to Yumabity to Kineta. lol this was a big scam for sure. Those PTI holders equity will be $0 for sure.

User Image Fullratio Posted - 2 months ago

$KA debt has plunged by 62% YoY and by 35% from the previous quarter: https://fullratio.com/stocks/nasdaq-ka/kineta

User Image NotHopeJustFacts Posted - 2 months ago

$KA awesome, anything including OTC is better than another RS, cannot understand why the did the past 1 for 7 (while still named Yumanity) instead of this, a POS should stay on OTC until they prove they can make $$$

User Image ThisJustin123 Posted - 2 months ago

$SMFL $KA $bgxx Why all the delisting on the same day?

User Image OpenOutcrier Posted - 2 months ago

$BGXX $KA $SMFL Bright Green, Kineta, and Smart for Life have all been delisted from Nasdaq and will trade on the pink sheets tomorrow. - @TradeHawk https://ooc.bz/l/42782

User Image TheTinyDevil Posted - 2 months ago

$SMFL $KA $BGXX As confirmation (since, you know, the FINRA site is a lier that does a fake news!):

User Image TheTinyDevil Posted - 2 months ago

$SMFL $KA $BGXX

User Image TheTinyDevil Posted - 2 months ago

***$BFI, keep your eyes peeled... $SMFL $KA $BGXX are all on THE list today... delisted from their exchange (all NASDAQ for these three) after today, trading OTC (over-the-counter) beginning tmrw, Sept. 19: https://otce.finra.org/otce/dailyList And if you're ever dealing with an oddball CBOE-listed stock on life support, keep an eye on this (as $SING and $VHAI found out recently): https://ww2.cboe.com/us/equities/listings/listed_products/suspensions_delistings/ Spread the word about these links... lots of delistings lately on tickers that get last-minute "liquidity pumps" which draw unwitting traders chasing. Then, the ppl savvy enough to simply check these lists (and it's really just basic info, like checking the halt list) inform the board and the clueless accuse them of lying. 🤷‍♂️

User Image TheTinyDevil Posted - 2 months ago

@TheRealMjBull @JimBull $SMFL $KA $BGXX are all on THE list, delisted after today: https://otce.finra.org/otce/dailyList And if you're ever dealing with an oddball CBOE-listed stock on life support, keep an eye on this: https://ww2.cboe.com/us/equities/listings/listed_products/suspensions_delistings/ Spread the word about these links... lots of delistings lately on tickers that get last-minute "liquidity pumps" which draw unwitting traders chasing. Then, the ppl savvy enough to simply check these lists (and it's really just basic info, like checking the halt list) inform the board and the clueless accuse them of lying. 🤷‍♂️

User Image TheTinyDevil Posted - 2 months ago

@Killastocker @MadHatterTrades74 $SMFL $KA $BGXX are all on THE list, delisted after today: https://otce.finra.org/otce/dailyList And if you're ever dealing with an oddball CBOE-listed stock on life support, keep an eye on this: https://ww2.cboe.com/us/equities/listings/listed_products/suspensions_delistings/ Spread the word about these links... lots of delistings lately on tickers that get last-minute "liquidity pumps" which draw unwitting traders chasing. Then, the ppl savvy enough to simply check these lists (and it's really just basic info, like checking the halt list) inform the board and the clueless accuse them of lying. 🤷‍♂️

User Image MadHatterTrades74 Posted - 2 months ago

$SMFL this is The determination letter from NASDAQ showing the company being do listed to OTC on September 19. Now this is for $KA stock however, I have not found any such letter for smart for life. That could just be because the company is so shitty that it failed to make that letter public as they are supposed to do Under the SEC regulations. This wouldn’t be the first time I’ve seen companies not adhered to guidelines.

User Image TradeHawk Posted - 2 months ago

$BGXX $KA $SMFL Bright Green, Kineta, and Smart for Life have all been delisted from Nasdaq and will trade on the pink sheets tomorrow.

User Image Line_Line Posted - 2 months ago

$KA added here, will add more

User Image positiveKevin Posted - 2 months ago

$KA I can’t see any news

Analyst Ratings
HC Wainwright & Co. Buy Jan 18, 24
HC Wainwright & Co. Buy Aug 21, 23
HC Wainwright & Co. Buy May 18, 23
HC Wainwright & Co. Buy May 1, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Bartoszek Raymond J. Director Director Dec 04 Buy 4.44 2,250 9,990 17,206 12/06/23
PHILIPS CRAIG W. President President Nov 28 Buy 3.2707 3,000 9,812 60,811 11/30/23
Iadonato Shawn Chief Executive Offi.. Chief Executive Officer Nov 28 Buy 3.42 5,000 17,100 675,230 11/30/23
PHILIPS CRAIG W. President President Sep 20 Buy 2.47 3,500 8,645 57,811 09/21/23
Kenny Pauline General Counsel & Se.. General Counsel & Secretary Sep 20 Buy 2.58 1,500 3,870 18,448 09/21/23
Iadonato Shawn Chief Executive Offi.. Chief Executive Officer Sep 20 Buy 2.5042 10,000 25,042 670,230 09/21/23
Bartoszek Raymond J. Director Director Sep 19 Buy 2.3725 2,000 4,745 14,956 09/21/23
Baker Keith Chief Financial Offi.. Chief Financial Officer Sep 18 Buy 2.1345 5,000 10,672 16,880 09/19/23
Bartoszek Raymond J. Director Director Sep 15 Buy 2.13 3,000 6,390 12,956 09/19/23
Guillaudeux Thierry Chief Scientific Off.. Chief Scientific Officer Sep 14 Buy 2.00 10,000 20,000 21,696 09/15/23
PHILIPS CRAIG W. President President Mar 17 Sell 4.68 2,103 9,842 66,977 03/21/23
Kenny Pauline General Counsel & Se.. General Counsel & Secretary Mar 17 Sell 4.48 1,311 5,873 17,806 03/21/23
Iadonato Shawn Chief Executive Offi.. Chief Executive Officer Mar 17 Sell 4.48 2,699 12,092 666,287 03/21/23
Peters Richard President and CEO President and CEO Dec 02 Sell 1.6913 10,890 18,418 90,028 12/06/22
Wyzga Michael D See Remarks See Remarks Dec 02 Sell 1.6913 3,116 5,270 13,997 12/06/22
Epstein Marie Principal Accounting.. Principal Accounting Officer Dec 02 Sell 1.691 1,976 3,341 8,883 12/06/22
Smith Devin Whittemore SVP and General Coun.. SVP and General Counsel Dec 02 Sell 1.691 3,116 5,269 13,961 12/06/22
Epstein Marie Principal Accounting.. Principal Accounting Officer Jun 03 Sell 1.1946 1,806 2,157 10,859 06/06/22
Smith Devin Whittemore SVP and General Coun.. SVP and General Counsel Jun 03 Sell 1.1946 2,923 3,492 17,077 06/06/22
Wyzga Michael D See Remarks See Remarks Jun 03 Sell 1.1946 2,887 3,449 17,113 06/06/22
Peters Richard President and CEO President and CEO Jun 03 Sell 1.1946 10,206 12,192 105,502 06/06/22
Peters Richard President and CEO President and CEO Mar 28 Sell 1.8455 10,715 19,775 115,708 03/30/22